Daprodustat(Jesduvroq)

As a prescription drug targeting hypoxia-inducible factor prolyl hydroxylases (HIF-PH1, PH2, PH3), Daprodustat was accepted for filing by the U.S. FDA in 2022 and formally approved in 2023. It should be used strictly under medical supervision.

Target of Action

Hypoxia-inducible factor prolyl hydroxylases (HIF-PH1, PH2, PH3)

Dosage and Administration

Route and frequency of administration for Daprodustat: Oral, once daily.

The dosage of Daprodustat should be adjusted based on the patient's actual condition. For specific adjustments, contact a physician and follow medical advice.

Recommended reading: Dosage and Administration of Daprodustat

Side Effects

Common side effects: Hypertension, thrombotic vascular events, etc.

Serious side effects: Cardiovascular events, gastrointestinal erosion, increased risk of heart failure hospitalization, etc.

Reference article: Side Effects of Daprodustat

Use in Special Populations

Pregnancy: Insufficient data to determine drug‑associated risks. Animal data suggest fetal risk.

Lactation: Advise lactating women not to breastfeed during treatment and for 1 week after the last dose.

Daily Precautions

1. Use of daprodustat increases the risk of death, myocardial infarction, stroke, thromboembolism, and vascular access thrombosis.

2. Use of daprodustat is associated with risk of hospitalization due to heart failure. Instruct patients about the signs and symptoms of heart failure and advise them to notify their healthcare provider immediately if such symptoms occur.

3. Use of daprodustat is associated with risk of hypertension. Instruct patients to regularly monitor blood pressure and take any prescribed antihypertensive medications as directed by their physician to reduce this risk.

from FDA，2023.02